Autopsy report · NCT02705378
The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit
Cause of deathStaffing, sites or logistics, also regulatory or ethics
“PI left institution. Protocol never submitted to the IRB, no contract executed only Confidentiality Agreement, and study not done.”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 3
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- University, hospital or other
- Conditions
- Constipation; Critical Illness
- Interventions
- Polyethylene glycol; naloxegol
- Participants
- 0
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Non-operative vs. Operative Management of Acute Appendicitis in Vulnerable Patient Populations
“Project did not receive final IRB approvals. PI decided to withdrawn research study.” - Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors
“No enrollment and PI requested study termination per IRB system.” - Supervisory Neglect, Non-Accidental Trauma, Brief Intervention, and Treatment Referral
“Study was never initiated. No IRB approval obtained, and no participants enrolled.” - Sensory-Play Based (SenPlay) Intervention for Young Children With or At Risk for ADHD
“Study closed by the IRB when PI did not submit for annual review.” - Real-time 3-Dimensional Echocardiography for Assessment of Cardiac Function and Congenital Heart Disease
“Study did not receive IRB approval.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.